Business Wire

Seoul Semiconductor Wins LED Bulb Litigation and Pursuit of Further Enforcement Actions against LED Lighting Retailers

Share

Seoul Semiconductor (KOSDAQ:046890) (collectively with Seoul Viosys Co., Ltd., “Seoul”), a leading global innovator of LED products and technology, announced that the U.S. Federal District Court for Nevada issued a judgment in favor of Seoul against Philcor T.V. & Electronic Leasing, Inc. dba energyavenue.com (“Philcor”), a company that sells LED lighting products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005043/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Seoul Semiconductor's Key Patented Technologies (Graphic: Business Wire)

Previously, Seoul filed a patent infringement lawsuit in Nevada District Court against Philcor asserting infringement of 8 LED patents.

In the lawsuit, Philcor acknowledged that LED products used in the accused products were manufactured by several third party suppliers and, although previously unknown to Philcor, Philcor did not dispute that those products infringed Seoul Semiconductor’s patents. Philcor also did not dispute the validity of Seoul Semiconductor’s patents and agreed to pay past damages, as well as a license fee, in order to affirm its commitment to respecting the intellectual property of patents in technologies for high-voltage operation (Acrich Driver), Acrich MJT (multi-junction technology; over-6V high power chip), filament LED bulb structure, LED packaging, LED epitaxial growth, and LED chip fabrication.

Other Enforcement Actions against LED Lighting Retailers
Seoul continues a series of enforcement actions to prevent distribution of suspected infringing products in the LED lighting market.

On March 2, Seoul filed a patent litigation for infringement of 10 LED patents in the Texas Northern District federal court against Service Lighting Electrical Supplies, Inc. – the operator of America’s largest online retail channel for LED bulbs: 1000bulbs.com.

On May 8, Seoul initiated a patent infringement lawsuit for infringement of 8 LED patents in the California Central District federal court against Bed Bath & Beyond Inc., an American chain of big-box retail stores having 1,550 stores. In the complaint, the accused products include various LED bulbs supplied by Feit Electric.

At the end of August, Seoul also filed a patent infringement lawsuit for infringement of 15 LED patents in the Texas Eastern District federal court against Fry’s Electronics, a retail company of consumer electronics – accusing UCD technology (KSF) that enables significant improvement of color gamut of LCD displays such as TVs and smartphones as well as optical lens technology of infringement.

In furtherance of its enforcement campaign, Seoul has also delivered notices to manufacturers of various LED lighting products, as well as their distributors, where it suspects infringement of its patents. Seoul has warned these companies that they need to stop using LEDs and any other components that may infringe upon Seoul’s patented technology.

Nam Ki-bum, Executive Vice President of the Lighting Department at Seoul, said, “In order to create fair competition in the market and make sure that intellectual property rights are respected, manufacturers as well as distributors should take active precautionary measures not to manufacture or sell infringing products” He added, “We will do our best to encourage a fair-competition environment, in which young entrepreneurs and small entities can succeed in the business world, relying on fair competition in the market and respecting hard-earned patented technology. This is one of the most valuable things Seoul Semiconductor is pursuing.”

About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Inc.
Jeonghee Kim, +82-70-4391-8311
jeonghee.kim@seoulsemicon.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

HiddenA line styled icon from Orion Icon Library.Eye